An exosome-mediated CRISPR/Cas9 delivery system was designed to target the oncogenic YTHDF1 gene in vivo, with the goal of depleting YTHDF1 to mitigate tumor progression by restoring antitumor immunity (159). Here, YTHDF1 is linked to neoplasm.